Befotertinib
Befotertinib (D-0316) is a third-generation EGFR tyrosine kinase inhibitor designed to target the T790M resistance mutation. It is a research compound used in preclinical studies, including in vitro cellular assays and in vivo models, for non-small cell lung cancer (NSCLC) .
Product Specifications
CAS Number
1835667-63-4
Product Name Alternative
D 0316, D0316, D-0316, Befotertinib, cancer, EGFR, Epidermal growth factor receptor, ErbB-1, Inhibitor, HER1, inhibit, kinase, non-small, NSCLC, lung, tyrosine
Field of Research
Cardiovascular Research, Signal Transduction
Purity
99.40% (May vary between batches)
Solubility
10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (3.52 mM) ; DMSO:60 mg/mL (105.71 mM)
Smiles
COc1cc (N (C) CCN (C) C) c (NC (=O) C=C) cc1Nc1nccc (n1) -c1cn (CC (F) (F) F) c2ccccc12
Molecular Formula
C29H32F3N7O2
Molecular Weight
567.61
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
K6221904 1.0 µg DNA
Aldh1l2 sgRNA CRISPR Lentivector (Rat) (Target 3)
Sign In for Pricing
View Details 
